Bortezomib
- PDF / 169,215 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 86 Downloads / 174 Views
1 S
Peripheral neuropathy: 4 case reports In an observational, prospective electronic bortezomib observational study of 96 patients enrolled between January 2006 and December 2010 who were previously treated with bortezomib for multiple myeloma (MM), 4 patients [ages and sexes not stated] were described, who developed peripheral neuropathy (PN) during treatment with bortezomib. The patients, who had history of grade 3–4 PN secondary to bortezomib, received retreatment with bortezomib [Velcade; dosages and routes not stated]. However, the patients developed grade 1 PN (1 patient), grade 3 PN (2 patients) and grade 4 PN (1 patient) [duration of treatments to reaction onsets not stated]. Bortezomib therapy was withdrawn in 3 patients with grade 3–4 PN [outcomes not stated]. Hulin C, et al. Bortezomib retreatment for relapsed and refractory multiple myeloma in real-world clinical practice. Health Science Reports 2: No. 1, Jan 2019. Available 803508740 from: URL: http://doi.org/10.1002/hsr2.104
0114-9954/20/1827-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved
Reactions 24 Oct 2020 No. 1827
Data Loading...
